{"url_path":"/sec/dare/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000025-index.html","accession_number":"0001401914-26-000025","cik":"0001401914","ticker":"DARE","issuer_name":"Dare Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000025-index.html","primary_entity_key":"0001401914","primary_entity_name":"Dare Bioscience, Inc."},"word_count":152,"has_tables":true,"body_markdown":"Item 2.02Results of Operations and Financial Condition.\n\nOn May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.\n\nThe information in this Item 2.02 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing."}